Clinical Trial

Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 11, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-14.
Status change: Not Yet Recruiting → Recruiting 2025-12-04
Trial Details
NCT Number NCT06643819
Lead Sponsor Chong Kun Dang Pharmaceutical
Conditions Essential Hypertension
Enrollment 324 participants
Start Date 2024-10-14
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-11